Abstract
Oral drug delivery is a preferred route because of good patient compliance. However, most peptide/ protein drugs are delivered via parenteral routes because of the absorption barriers in the gastrointestinal (GI) tract such as enzymatic degradation by proteases and low permeability acrossthe biological membranes. To overcome these barriers, different formulation strategies for oral delivery of biomacromolecules have been proposed, including lipid based formulations and polymer-based particulate drug delivery systems (DDS). The aim of this review is to summarize the existing knowledge about oral delivery of peptide/protein drugs and to provide an overview of formulationand characterization strategies. For a better understanding of the challenges in oral delivery of peptide/protein drugs, the composition of GI fluids and the digestion processes of different kinds of excipients in the GI tract are summarized. Additionally, the paper provides an overview of recent studies on characterization of solid drug carriers for peptide/protein drugs, drug distribution in particles, drug release and stability in simulated GI fluids, as well as the absorption of peptide/protein drugs in cell-based models. The use of biorelevant media when applicable can increase the knowledge about the quality of DDS for oral protein delivery. Hopefully, the knowledge provided in this review will aid the establishment of improved biorelevant models capable of forecasting the performance of particulate DDS for oral peptide/protein delivery.
Keywords: Oral drug delivery, peptide/protein drugs, particulate delivery systems, solid lipid particles, drug release mechanism, stability, lipolysis, in vitro methods.
Current Pharmaceutical Design
Title:Characterization of Particulate Drug Delivery Systems for Oral Delivery of Peptide and Protein Drugs
Volume: 21 Issue: 19
Author(s): Philip Carsten Christophersen, Mathias Fano, Lasse Saaby, Mingshi Yang, Hanne Mørck Nielsen and Huiling Mu
Affiliation:
Keywords: Oral drug delivery, peptide/protein drugs, particulate delivery systems, solid lipid particles, drug release mechanism, stability, lipolysis, in vitro methods.
Abstract: Oral drug delivery is a preferred route because of good patient compliance. However, most peptide/ protein drugs are delivered via parenteral routes because of the absorption barriers in the gastrointestinal (GI) tract such as enzymatic degradation by proteases and low permeability acrossthe biological membranes. To overcome these barriers, different formulation strategies for oral delivery of biomacromolecules have been proposed, including lipid based formulations and polymer-based particulate drug delivery systems (DDS). The aim of this review is to summarize the existing knowledge about oral delivery of peptide/protein drugs and to provide an overview of formulationand characterization strategies. For a better understanding of the challenges in oral delivery of peptide/protein drugs, the composition of GI fluids and the digestion processes of different kinds of excipients in the GI tract are summarized. Additionally, the paper provides an overview of recent studies on characterization of solid drug carriers for peptide/protein drugs, drug distribution in particles, drug release and stability in simulated GI fluids, as well as the absorption of peptide/protein drugs in cell-based models. The use of biorelevant media when applicable can increase the knowledge about the quality of DDS for oral protein delivery. Hopefully, the knowledge provided in this review will aid the establishment of improved biorelevant models capable of forecasting the performance of particulate DDS for oral peptide/protein delivery.
Export Options
About this article
Cite this article as:
Christophersen Carsten Philip, Fano Mathias, Saaby Lasse, Yang Mingshi, Nielsen Mørck Hanne and Mu Huiling, Characterization of Particulate Drug Delivery Systems for Oral Delivery of Peptide and Protein Drugs, Current Pharmaceutical Design 2015; 21 (19) . https://dx.doi.org/10.2174/1381612821666150416100943
DOI https://dx.doi.org/10.2174/1381612821666150416100943 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thyroid Cancer and Nodules in Graves’ Disease: A Single Center Experience
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Thyroid Hormones and their Metabolites: Biological Roles and Association with Non-Alcoholic Fatty Liver Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science The Role of Mass Spectrometry in the “Omics” Era
Current Organic Chemistry Polyphenolic Compounds: Interactions with the Gut and Implications for Human Health
Current Medicinal Chemistry Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design Programmed Cell Death Protein 1 (PD-1) in Relation to PANoptosis: Immune Pharmacological Targets for Management of Breast Adenocarcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Targets of Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Usefulness of Abbreviated MRI Protocol in Breast Cancer Detection
Current Medical Imaging Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Potential Applications of Bacterial Cellulose in Environmental and Pharmaceutical Sectors
Current Pharmaceutical Design Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets